

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.




**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/56, C07J 41/00, 31/00, 13/00, 9/00, 5/00, 7/00, 3/00, 1/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/04535 (43) International Publication Date: 16 February 1995 (16.02.95)</p>
<p>(21) International Application Number: PCT/US94/08767 (22) International Filing Date: 2 August 1994 (02.08.94) (30) Priority Data: 08/102,767 6 August 1993 (06.08.93) US (71) Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US). (72) Inventors: D'AMATO, Robert, John; 911 Forest Road, Lancaster, PA 17601 (US). FOLKMAN, Moses, Judah; 18 Chatham Circle, Brookline, MA 02146 (US). (74) Agent: FREEMAN, John, W.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD). Published With international search report.</p>
<p>(54) Title: ESTROGENIC COMPOUNDS AS ANTI-MITOTIC AGENTS</p>		
 <p>COLCHICINE</p>	 <p>2-METHOXYESTRADIOL</p>	 <p>COMBRETASTATIN A-4</p>
<p>(57) Abstract The application discloses methods of making medicaments for treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of general formulae found above in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

ESTROGENIC COMPOUNDS
AS ANTI-MITOTIC AGENTS

Background of the Invention

5 This invention relates to treating disease states characterized by abnormal cell mitosis.

 Cell mitosis is a multi-step process that includes cell division and replication (Alberts, B. et al. In *The Cell*, pp. 652-661 (1989); Stryer, E. *Biochemistry* (1988)). Mitosis is characterized by the intracellular movement and segregation of organelles, including mitotic spindles and chromosomes. Organelle movement and segregation are facilitated by the polymerization of the cell protein tubulin. Microtubules
10 are formed from α and β tubulin polymerization and the hydrolysis of GTP. Microtubule formation is important for cell mitosis, cell locomotion, and the movement of highly specialized cell structures such as cilia and flagella.

20 Microtubules are extremely labile structures that are sensitive to a variety of chemically unrelated anti-mitotic drugs. For example, colchicine and nocadazole are anti-mitotic drugs that bind tubulin and inhibit tubulin polymerization (Stryer, E. *Biochemistry* (1988)).
25 When used alone or in combination with other therapeutic drugs, colchicine may be used to treat cancer (WO-9303729-A, published March 4, 1993; J03240726-A, published October 28, 1991), alter neuromuscular function, change blood pressure, increase sensitivity to
30 compounds affecting sympathetic neuron function, depress respiration, and relieve gout (*Physician's Desk Reference*, Vol. 47, p. 1487, (1993)).

 Estradiol and estradiol metabolites such as 2-methoxyestradiol have been reported to inhibit cell
35 division (Seegers, J.C. et al. *J. Steroid Biochem.* 32,

- 2 -

797-809 (1989); Lottering, M-L. et al. *Cancer Res.* 52, 5926-5923 (1992); Spicer, L.J. and Hammond, J.M. *Mol. and Cell. Endo.* 64, 119-126 (1989); Rao, P.N. and Engelberg, J. *Exp. Cell Res.* 48, 71-81 (1967)). However, the
5 activity is variable and depends on a number of *in vitro* conditions. For example, estradiol inhibits cell division and tubulin polymerization in some *in vitro* settings (Spicer, L.J. and Hammond, J.M. *Mol. and Cell. Endo.* 64, 119-126 (1989); Ravindra, R., J. *Indian Sci.*
10 64(c) (1983)), but not in others (Lottering, M-L. et al. *Cancer Res.* 52, 5926-5923 (1992); Ravindra, R., J. *Indian Sci.* 64(c) (1983)). Estradiol metabolites such as 2-methoxyestradiol will inhibit cell division in selected *in vitro* settings depending on whether the cell culture
15 additive phenol red is present and to what extent cells have been exposed to estrogen. (Seegers, J.C. et al. Joint NCI-IST Symposium. Biology and Therapy of Breast Cancer. 9/25-9/27, 1989, Genoa, Italy, Abstract A58).

Numerous diseases are characterized by abnormal
20 cell mitosis. For example, uncontrolled cell mitosis is a hallmark of cancer. In addition, cell mitosis is important for the normal development of the embryo, formation of the corpus luteum, wound healing, inflammatory and immune responses, angiogenesis and
25 angiogenesis related diseases.

Summary of the Invention

I have discovered that certain compounds within the scope of the general formulae set forth below in the claims are useful for treating mammalian diseases
30 characterized by undesired cell mitosis. Without wishing to bind myself to any particular theory, such compounds generally inhibit microtubule formation and tubulin polymerization and/or depolymerization. Compounds within the general formulae having said inhibiting activity are
35 preferred. Preferred compositions may also exhibit a

- 3 -

change (increase or decrease) in estrogen receptor binding, improved absorption, transport (e.g. through blood-brain barrier and cellular membranes), biological stability, or decreased toxicity. I have also discovered
5 certain compounds useful in the method, as described by the general formulae of the claims.

A mammalian disease characterized by undesirable cell mitosis, as defined herein, includes but is not limited to excessive or abnormal stimulation of
10 endothelial cells (e.g., atherosclerosis), solid tumors and tumor metastasis, benign tumors, for example, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, vascular malfunctions, abnormal wound healing, inflammatory and immune disorders,
15 Bechet's disease, gout or gouty arthritis, abnormal angiogenesis accompanying: rheumatoid arthritis, psoriasis, diabetic retinopathy, and other ocular angiogenic diseases such as retinopathy of prematurity (retrolental fibroplastic), macular degeneration, corneal
20 graft rejection, neovascular glaucoma and Osler Weber syndrome. Other undesired angiogenesis involves normal processes including ovulation and implantation of a blastula. Accordingly, the compositions described above can be used to block ovulation and implantation of a
25 blastula or to block menstruation (induce amenorrhea).

The bond indicated by C•••C is absent or, in combination with the C---C bond is the unit HC=CH.

Other features and advantages of the invention will be apparent from the following description of
30 preferred embodiments thereof.

Description of the Preferred Embodiments

The drawings are first described.

Fig. 1 is a graph illustrating the inhibition of tubulin polymerization by 2-methoxyestradiol described by
35 Example 1 below.

- 4 -

Fig. 2 is a graph illustrating the inhibition of colchicine binding to tubulin by 2-methoxyestradiol described by Example 2 below.

Fig. 3 depicts: I. colchicine, 2-methoxyestradiol and combretastatin A-4, and II. various estradiol derivatives comprising colchicine (a-c) or combretastatin A-4 (d) structural motifs as described below.

Compounds According to the Invention

As described below, compounds that are useful in accordance with the invention include novel estradiol derivatives that bind tubulin, inhibit microtubule formation or exhibit anti-mitotic properties. Specific compounds according to the invention are described below. Those skilled in the art will appreciate that the invention extends to other compounds within the formulae given in the claims below, having the described characteristics. These characteristics can be determined for each test compound using the assays detailed below and elsewhere in the literature.

Without wishing to bind myself to specific mechanisms or theory, it appears that certain compounds that are known to inhibit microtubule formation, bind tubulin and exhibit anti-mitotic properties such as colchicine and combretastatin A-4 share certain structural similarities with estradiol. Fig. 3 illustrates the molecular formulae of estradiol, colchicine, combretastatin A-4, and improved estradiol derivatives that bind tubulin inhibit microtubule assembly and exhibit anti-mitotic properties. Molecular formulae are drawn and oriented to emphasize structural similarities between the ring structures of colchicine, combretastatin A-4, estradiol, and certain estradiol derivatives. Estradiol derivatives are made by incorporating colchicine or combretastatin A-4 structural motifs into the steroidal backbone of estradiol.

- 5 -

Figure 3, part I, depicts the chemical formulae of colchicine, 2-methoxyestradiol and combretastatin A-4. Figure 3, part IIa-d, illustrates estradiol derivatives that comprise structural motifs found in colchicine or combretastatin A-4. For example, part II a-c shows estradiol derivatives with an A and/or B ring expanded from six to seven carbons as found in colchicine and part II d depicts an estradiol derivative with a partial B ring as found in combretastatin A-4. Each C ring of an estradiol derivative, including those shown in Figure 3, may be fully saturated as found in 2-methoxyestradiol. R_{1-6} represent a subset of the substitution groups found in the claims. Each R_1 - R_6 can independently be defined as $-R_1$, OR_1 , $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$, or $-C\equiv CH$.

15 Anti-mitotic Activity In Situ

Anti-mitotic activity is evaluated *in situ* by testing the ability of an improved estradiol derivative to inhibit the proliferation of new blood vessel cells (angiogenesis). A suitable assay is the chick embryo chorioallantoic membrane (CAM) assay described by Crum et al. *Science* 230:1375 (1985). See also, U.S. Patent 5,001,116, hereby incorporated by reference, which describes the CAM assay. Briefly, fertilized chick embryos are removed from their shell on day 3 or 4, and a methylcellulose disc containing the drug is implanted on the chorioallantoic membrane. The embryos are examined 48 hours later and, if a clear avascular zone appears around the methylcellulose disc, the diameter of that zone is measured. Using this assay, a 100mg disk of the estradiol derivative 2-methoxyestradiol was found to inhibit cell mitosis and the growth of new blood vessels after 48 hours. This result indicates that the anti-mitotic action of 2-methoxyestradiol can inhibit cell mitosis and angiogenesis.

- 6 -

Anti-Mitotic Activity In Vitro

Anti-mitotic activity can be evaluated by testing the ability of an estradiol derivative to inhibit tubulin polymerization and microtubule assembly *in vitro*.

- 5 Microtubule assembly is followed in a Gilford recording spectrophotometer (model 250 or 2400S) equipped with electronic temperature controllers. A reaction mixture (all concentrations refer to a final reaction volume of 0.25 μ l) contains 1.0M monosodium glutamate (ph 6.6),
10 1.0mg/ml (10 μ M) tubulin, 1.0 mM MgCl₂, 4% (v/v) dimethylsulfoxide and 20-75 μ M of a composition to be tested. The 0.24ml reaction mixtures are incubated for 15 min. at 37°C and then chilled on ice. After addition of 10 μ l 2.5mM GTP, the reaction mixture is transferred to
15 a cuvette at 0°C, and a baseline established. At time zero, the temperature controller of the spectrophotometer is set at 37°C. Microtubule assembly is evaluated by increased turbidity at 350 nm. Alternatively, inhibition of microtubule assembly can be followed by transmission
20 electron microscopy as described in Example 2 below.

Indications

- The invention can be used to treat any disease characterized by abnormal cell mitosis. Such diseases include, but are not limited to: abnormal stimulation of
25 endothelial cells (e.g., atherosclerosis), solid tumors and tumor metastasis, benign tumors, for example, hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, vascular malfunctions, abnormal wound healing, inflammatory and immune disorders,
30 Bechet's disease, gout or gouty arthritis, abnormal angiogenesis accompanying: rheumatoid arthritis, psoriasis, diabetic retinopathy, and other ocular angiogenic diseases such as retinopathy of prematurity (retrolental fibroplastic), macular degeneration, corneal

- 7 -

graft rejection, neurovascular glaucoma and Oster Webber syndrome.

Improved Estradiol Derivative Synthesis

Known compounds that are used in accordance with
5 the invention and precursors to novel compounds according to the invention can be purchased, e.g., from Sigma Chemical Co., St. Louis, Steroloids and Research Plus. Other compounds according to the invention can be synthesized according to known methods from publicly
10 available precursors.

The chemical synthesis of estradiol has been described (Eder, V. et al., *Ber* 109, 2948 (1976); Oppolzer, D.A. and Roberts, D.A. *Helv. Chim. Acta.* 63, 1703, (1980)). Synthetic methods for making seven-
15 membered rings in multi-cyclic compounds are known (Nakamura, T. et al. *Chem. Pharm. Bull.* 10, 281 (1962); Sunagawa, G. et al. *Chem. Pharm. Bull.* 9, 81 (1961); Van Tamelen, E. E. et al. *Tetrahedron* 14, 8-34 (1961); Evans, D. E. et al. *JACS* 103, 5813 (1981)). Those skilled in
20 the art will appreciate that the chemical synthesis of estradiol can be modified to include 7-membered rings by making appropriate changes to the starting materials, so that ring closure yields seven-membered rings. Estradiol or estradiol derivatives can be modified to include
25 appropriate chemical side groups according to the invention by known chemical methods (*The Merck Index*, 11th Ed., Merck & Co., Inc., Rahway, NJ USA (1989), pp. 583-584).

Administration

30 The compositions described above can be provided as physiologically acceptable formulations using known techniques, and these formulations can be administered by standard routes. In general, the combinations may be administered by the topical, oral, rectal or parenteral
35 (e.g., intravenous, subcutaneous or intramuscular) route.

- 8 -

In addition, the combinations may be incorporated into biodegradable polymers allowing for sustained release, the polymers being implanted in the vicinity of where delivery is desired, for example, at the site of a tumor.

- 5 The biodegradable polymers and their use are described in detail in Brem et al., *J. Neurosurg.* 74:441-446 (1991).

The dosage of the composition will depend on the condition being treated, the particular derivative used, and other clinical factors such as weight and condition
10 of the patient and the route of administration of the compound. However, for oral administration to humans, a dosage of 0.01 to 100 mg/kg/day, preferably 0.01-1 mg/kg/day, is generally sufficient.

The formulations include those suitable for oral,
15 rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intraocular, intratracheal, and epidural) administration. The formulations may conveniently be presented in unit dosage
20 form and may be prepared by conventional pharmaceutical techniques. Such techniques include the step of bringing into association the active ingredient and the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately
25 bringing into associate the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units
30 such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil emulsion and as a
35 bolus, etc.

- 9 -

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Molded tables may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.

10 The tablets may optionally coated or scored and may be formulated so as to provide a slow or controlled release of the active ingredient therein.

Formulations suitable for topical administration in the mouth include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the ingredient to be administered in a suitable liquid carrier.

20 Formulations suitable for topical administration to the skin may be presented as ointments, creams, gels and pastes comprising the ingredient to be administered in a pharmaceutical acceptable carrier. A preferred topical delivery system is a transdermal patch containing the ingredient to be administered.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for nasal administration, wherein the carrier is a solid, include a coarse powder having a particle size, for example, in the range of 20 to 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose. Suitable formulations, wherein the

- 10 -

carrier is a liquid, for administration, as for example, a nasal spray or as nasal drops, include aqueous or oily solutions of the active ingredient.

Formulations suitable for vaginal administration
5 may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such as carriers as are known in the art to be appropriate.

Formulations suitable for parenteral
10 administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile
15 suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) conditions requiring only the addition of
20 the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tables of the kind previously described.

25 Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of the administered ingredient.

It should be understood that in addition to the
30 ingredients, particularly mentioned above, the formulations of this invention may include other agents convention in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include flavoring agents.

- 11 -

Example 1:

Figure 1 illustrates the inhibition of tubulin polymerization by 2-methoxyestradiol.

A. Each reaction mixture (all concentrations refer to the final reaction volume of 0.25 ml) contained 1.0 M monosodium glutamate (pH 6.6), 1.0 mg/ml (10 μ M) tubulin, 1.0 mM MgCl_2 , 4% (v/v) dimethylsulfoxide, and either 0 (curve 1), 20 μ M (curve 2), 40 μ M (curve 3), or 75 μ M (curve 4) 2-methoxyestradiol. The 0.24 ml reaction mixtures were incubated for 15 min at 37°C and chilled on ice. After addition of 10 μ l of 2.5 mM GTP the reaction mixtures were transferred to cuvettes held at 0°C, and baselines were established. At time zero the temperature controller was set at 37°C. At the times indicated by the vertical dashed lines the temperature controller was set at the indicated temperatures.

B. Each reaction mixture contained 0.8 M monosodium glutamate (pH 6.6), 1.2 mg/ml (12 μ M) tubulin, 4% (v/v) dimethylsulfoxide, and either 0 (curve 1), 1.0 μ M (curve 2), 2.0 μ M (curve 3), 3.0 μ M (curve 4), or 4.0 μ M (curve 5) 2-methoxyestradiol. The 0.24 ml reaction mixtures were incubated for 15 min at 26°C and chilled on ice. After addition of 10 μ l of 10 mM GTP the reaction mixtures were transferred to cuvettes held at 0°C, and baselines were established. At time zero the temperature controller was set at 26°C. At the time indicated by vertical dashed line the temperature controller was set at 0°C.

- 12 -

Example 2:

Transmission electron microscopy (TEM) can show differences between the morphology of polymerized tubulin formed in the absence or presence of 2-methoxyestradiol.

5 After a 30 min incubation (37°C) of reaction mixtures containing the components described in Example 1, 75 μ M 2-methoxyestradiol was added, and aliquots were placed on 200-mesh carbon coated copper grids and stained with 0.5% (w/v) uranyl acetate. TEM magnifications from 23,100X to
10 115,400X were used to visualize differences in tubulin morphology.

Example 3:

Figure 2 illustrates that 2-methoxyestradiol inhibits colchicine binding to tubulin. Reaction

15 conditions were as described in the text, with each reaction mixture containing 1.0 μ M tubulin, 5% (v/v) dimethyl sulfoxide, 5 μ M [3 H]colchicine, and inhibitor at the indicated concentrations. Incubation was for 10 min at 37°C. Symbols as follows: o, 2-methoxyestradiol; •,
20 combretastatin A-4; Δ , dihydrocombretastatin A-4. Combretastatin A-4 and dihydrocombretastatin A-4 are compounds with anti-mitotic activity similar to colchicine.

Example 4:

25 Table 1 illustrates the inhibitory effects on tubulin polymerization *in vitro* exhibited by estradiol or estradiol derivatives, plant anti-mitotic compounds such as colchicine, combretastatin A-4 or other plant compounds. The method is given in Example 1.

30 Example 5:

Table 2 lists estrogens, estradiol or estradiol derivatives that inhibit colchicine binding to tubulin, by the method given in Example 3.

- 13 -

Table 1

	<u>Estrogenic Compound</u>	<u>IC₅₀ (μM \pm S.D.)</u>
	2-Methoxyestradiol	1.9 \pm 0.2
	Diethylstilbestrol	2.4 \pm 0.4
5	2-Bromoestradiol	4.5 \pm 0.6
	2-Methoxyestrone	8.8 \pm 1
	17-Ethynylestradiol	10.0 \pm 2
	2-Fluoroestradiol	27.0 \pm 6
	Estradiol	30.0 \pm 6
10	Estrone	> 40
	2-Methoxy-17-ethynylestradiol	> 40
	Estriol	> 40
	2-Methoxyestriol	> 40
	Estradiol-3-O-methyl ether	> 40
15	2-Methoxyestradiol-3-O-methyl ether	> 40
	4-Methoxyestradiol	> 40
	4-Methoxyestradiol-3-O-methyl ether	> 40

	<u>Plant Products</u>	<u>IC₅₀ (μM \pm S.D.)</u>
20	Colchicine	0.80 \pm 0.07
	Podophyllotoxin	0.46 \pm 0.02
	Combretastatin A-4	0.53 \pm 0.05
	Dihydrocombretastatin A-4	0.63 \pm 0.03

- 25 IC₅₀ values are defined as the concentration of an estradiol derivative required to inhibit tubulin polymerization by 50%. IC₅₀ values were obtained in at least two independent experiments for non-inhibitory agents (IC₅₀ > 40 μ M) and at least three independent
- 30 experiments for inhibitory compounds. IC₅₀ values were obtained graphically, and average values are presented. S.D., standard deviation.

- 14 -

Table 2

<u>Estrogenic Compound</u>	<u>Percent inhibition \pm S.D.</u>
2-Methoxyestradiol	82 \pm 2
2-Methoxyestrone	57 \pm 6
5 17-Ethynylestradiol	50 \pm 7
Estradiol	38 \pm 4
Diethylstilbestrol	30 \pm 4


Reaction conditions were described in Example 3, with
10 each reaction mixture containing 1.0 μ M tubulin, 5% (v/v)
dimethyl sulfoxide, 2 μ M [3 H]colchicine, and 100 μ M
inhibitor. Incubation was for 10 min at 37°C. Average
values obtained in three independent experiments are
presented in the table, except for 2-methoxyestrone,
15 which was only examined twice. S.D., standard deviation.

What is claimed is:

- 15 -

Claims

1. A method of making a medicament which is capable of inhibiting abnormal cell mitosis, said medicament comprising, in a pharmaceutically acceptable carrier, a cell mitosis-inhibiting compound of the formula:



wherein:

I. R_a - R_o are defined as follows:

- 10 A) each R_a , R_b , R_c , R_d , R_e , R_f , R_i , R_j , R_k , R_l , R_m , R_o , independently is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, or $-I$; and R_g is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$, or $-C\equiv CH$;


15 or

- 16 -


- B) each $R_a, R_b, R_c, R_f, R_k, R_l, R_o,$
independently is $-R_1, -OR_1, -OCOR_1,$
 $-SR_1,$
 $-F, -NHR_2, -Br,$ or $-I$; and each $R_d, R_e,$
 $R_i, R_j, R_m,$ independently is $=O, -R_1,$
 $-OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br$ or $-I$;
and R_g is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F,$
 $-NHR_2, -Br, -I,$ or $-C\equiv CH$;

and

10 II. Z' is defined as follows:




or




and


25 III. Z'' is defined as follows:



- 17 -



or




and

- IV. provided that when each $\text{R}_b, \text{R}_c, \text{R}_d, \text{R}_e, \text{R}_i, \text{R}_j, \text{R}_k,$
 R_l, R_m and R_o is H;
 30 R_f is $-\text{CH}_3$;
 R_g is $-\text{OH}$;
 Z' is $>\text{COH}$; and
 Z'' is $>\text{CH}_2$;
 then R_a is not $-\text{H}$;
 35 where, in each formula set forth above, each R_1 and R_2
 independently is $-\text{H}$, or substituted or unsubstituted
 alkyl, alkenyl or alkynyl group of 1-6 carbons.

- 18 -

2. A method of making a medicament which is capable of inhibiting abnormal cell mitosis, said medicament comprising, in a pharmaceutically acceptable carrier, a cell mitosis inhibiting compound of the formula:



wherein:


I. R_a - R_k are defined as follows:

- 10 A) each R_a , R_b , R_c , R_d , R_g , R_h , R_i , R_k independently is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, or $-I$; and R_e is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$ or $-C\equiv CH$;
- or
- 15 B) each R_a , R_b , R_c , R_d , R_k , independently is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, or $-I$; and each R_e , R_g , R_h , R_i , independently is $=O$, $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-Br$, or $-I$; and R_e is $=O$, $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-Br$, $-I$ or $-C\equiv CH$;
- 20


and

- 19 -

II. Z' is defined as follows:










or




15 and


III. Z'' is defined as follows:



- 20 -




or



3. A method of making a medicament which is capable of inhibiting abnormal cell mitosis, said medicament comprising, in a pharmaceutically acceptable carrier, a cell mitosis-inhibiting compound of the

25 formula:



- 21 -

wherein:

I. R_a - R_o are defined as follows:

- 5 A) each $R_a, R_b, R_c, R_d, R_e, R_f, R_i, R_j, R_k, R_l, R_m, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br$, or $-I$; and R_g is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;


or

- 10 B) each $R_a, R_b, R_c, R_f, R_k, R_l$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br$, or $-I$; and each $R_d, R_e, R_i, R_j, R_m, R_o$ independently is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br$, or $-I$; and R_g is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;
- 15








and

II. Z is defined as follows:


- 20 A) Z is Y , where Y is $-O-, -N-, >CHR_1,$



- 22 -



or




is $-R_1$, $-OR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$ or $-I$;

where, in each formula set forth above, each R_1 and R_2 independently is $-H$, or substituted or unsubstituted alkyl, alkenyl or alkynyl group of 1-6 carbons.

4. A method of making a medicament which is capable of inhibiting abnormal cell mitosis, said medicament comprising, in a pharmaceutically acceptable carrier, a cell mitosis-inhibiting compound of the formula:

- 23 -



wherein:

I. R_a-R_k are defined as follows:

A) each R_a, R_b, R_c, R_d, R_g, R_h, R_i, R_k independently is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br, or -I; and R_e is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br, -I or -C≡CH;

or

B) each R_a, R_b, R_c, R_d, independently is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br, or -I and each R_g, R_h, R_i, R_k independently is =O, -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br or -I; and R_e is =O, -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br, -I or -C≡CH;


and

II. Z is defined as follows:


- 24 -

A) Z is Y, where Y is -O- , -N- , >CHR_1 ,



5





10





15





20



25



30



or

35

B) Z is -Y-CH- or -CH-Y- , where R_n




is -R_1 , -OR_1 , -SR_1 , -F , -NHR_2 , -Br or -I ;

- 25 -

where, in each formula set forth above, each R_1 and R_2 independently is -H, or substituted or unsubstituted alkyl, alkenyl or alkynyl group of 1-6 carbons.

5. A method of making a medicament which is capable of inhibiting abnormal cell mitosis, said medicament comprising, in a pharmaceutically acceptable carrier, a cell mitosis-inhibiting compound of the formula:



10 wherein:

I. R_a - R_o are defined as follows:

15 A) each $R_a, R_b, R_c, R_d, R_e, R_f, R_g, R_h, R_j, R_k, R_l, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$; and R_i is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;

or

B) each $R_a, R_d, R_f, R_j, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1,$

- 26 -

-F, -NHR₂, -Br, or -I; and each R_b, R_c, R_e, R_g, R_h, R_k, R_l independently is =O, -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br or -I; and R_i is =O, -R₁, -OR₁, -OCOR₁, -SR₁, -F, -Br, -I or -C≡CH;

or

C) each R_a, R_b, R_c, R_d, R_f, R_j, R_m, R_n, R_o independently is -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₂, -Br, -I and each R_e, R_g, R_h, R_k, R_l independently is =O, -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br or -I; and R_i is =O, -R₁, -OR₁, -OCOR₁, -SR₁, -F, -Br, -I or -C≡CH;

II. Z is defined as follows:

A) Z is X, where X is $\begin{array}{c} \text{O} \\ | \\ >\text{COR}_1, >\text{CC}-\text{R}_1, >\text{CC}-\text{OR}_1, \end{array}$

$\begin{array}{c} \text{OH} \quad \text{OH} \\ | \quad | \\ >\text{CC}-\text{R}_1, >\text{CC}-\text{OR}; \end{array}$

or


B) Z is $\begin{array}{c} \text{=C}-\text{X}'- \\ | \\ \text{R}_p \end{array}$ or $\begin{array}{c} -\text{X}'-\text{C=} \\ | \\ \text{R}_p \end{array}$, where R_p

is -R₁, -OR₁, -SR₁, -F, -NHR₂, -Br or -I; and X' is X, as defined above; or X' is >C=O;

where, in each formula set forth above, each R₁ and R₂ independently is -H, or substituted or unsubstituted alkyl, alkenyl or alkynyl group of 1-6 carbons; and the bond indicated by C•••C is absent or, in combination with the C-C bond, is the unit HC=CH.

- 27 -

6. A method of making a medicament which is capable of inhibiting abnormal cell mitosis, said medicament comprising, in a pharmaceutically acceptable carrier, a cell mitosis-inhibiting compound of the
5 formula:



wherein:

I. R_a - R_o are defined as follows:

10 A) each R_a , R_b , R_c , R_e , R_g , R_h , R_k , R_l , R_m , R_n , R_o independently is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, or $-I$; and R_1 is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$ or $-C\equiv CH$;

or

15 B) each R_a , R_e , R_l , R_m , R_n , R_o independently is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$ and each R_b , R_c , R_g , R_h is $=O$,

- 28 -

$-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_1$, $-Br$
or $-I$; and R_1 is $=O$, $-R_1$, $-OR_1$, $-OCOR_1$,
 $-SR_1$, $-F$, $-NHR_1$, $-Br$, $-I$ or $-C\equiv CH$;

or

5

C) each R_a , R_b , R_c , R_d , R_k , R_m , R_n , R_o
independently is $-R_1$, $-OR_1$, $-OCOR_1$,
 $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$, and each R_h ,
 R_i independently is $=O$, $-R_1$, $-OR_1$,
10 $-OCOR_1$, $-SR_1$, $-F$, $-NHR_1$, $-Br$ or $-I$; and
 R_l is $=O$, $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$,
 $-NHR_1$, $-Br$, $-I$ or $-C\equiv CH$;

and

I. Z is defined as follows:

15

A) Z is X, where X is $\begin{array}{c} O \\ | \\ >COR_1 \end{array}$, $\begin{array}{c} O \\ | \\ >CC-R_1 \end{array}$, $\begin{array}{c} O \\ | \\ >CC-OR_1 \end{array}$,

$\begin{array}{c} OH \\ | \\ >CC-R_1 \end{array}$, $\begin{array}{c} OH \\ | \\ >CC-OR \end{array}$;

20 or


B) Z is $\begin{array}{c} R_p \\ | \\ =C-X' \end{array}$ or $\begin{array}{c} R_p \\ | \\ -X'-C= \end{array}$, where R_p

is $-R_1$, $-OR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$ or
25 $-I$, and X' is X, as defined above;
or X' is $=O$;

where, in each formula set forth above, each R_1 and R_2
independently is $-H$, or substituted or unsubstituted
alkyl, alkenyl or alkynyl group of 1-6 carbons; and the
30 bond indicated by $C\equiv C$ is absent or, in combination with
the $C-C$ bond is the unit $HC=CH$.

7. A compound of the general formula below, said
compound being a cell-mitosis-inhibiting compound:

- 29 -



wherein:

I. $R_a - R_0$ are defined as follows:

5

(A) each $R_a, R_b, R_c, R_d, R_e, R_f, R_i, R_j, R_k, R_l, R_m, R_o$, independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br$, or $-I$; and R_g is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;

or

10

(B) each $R_a, R_b, R_c, R_f, R_k, R_l, R_o$, is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, or $-I$; and each R_d, R_e, R_i, R_j, R_m , independently is $=O$, $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$ or $-I$; and R_g is $=O$, $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$, $-I$ or $-C\equiv CH$;


15

- 30 -

and

II. Z' is defined as follows:

5 A) Z' is X, where X is $\overset{\text{O}}{\underset{|}{>\text{C}}}\text{OR}_1$, $\overset{\text{O}}{\underset{|}{>\text{C}}}\text{-R}_1$,



or







10 B) Z' is $\overset{\text{R}_n}{\underset{|}{=}\text{C-X'}}$ or $\text{-X'-}\overset{\text{R}_n}{\underset{|}{=}\text{C}}$, where R_n

is -R₁, -OR₁, -SR₁, -F, -NHR₂, -Br or
-I; or X' is X, as defined above; or
15 X' is >C=O;





and

III. Z'' is defined as follows:

20 A) Z'' is Y, where Y is $\overset{\text{R}_1}{\underset{|}{-\text{O}-}}$, $\overset{\text{R}_1}{\underset{|}{-\text{N}-}}$, >CHR_1 ,



- 31 -



or

B) Z" is $-Y-\underset{\substack{| \\ R_p}}{CH}-$ or $-\underset{\substack{| \\ R_p}}{CH}-Y-$ where R_p is $-R_1, -OR_1, -SR_1, -F, -NHR_2, -Br$ or $-I$;

provided that when:

3) each $R_b, R_c, R_d, R_e, R_j, R_k, R_l, R_m$, is $-H$; R_f is $-CH_3$;
$$\begin{array}{c} O \\ | \\ R_g \text{ is } -OH, -OCCH_3; \end{array}$$
 R_i is $-H, -OH$, or $=O$; R_o is $-H$ or $-Br$; Z' is $>COH$; and Z'' is $>CH_2$ or $-OH$; then R_a is not $-F, -Br, -OH$ or $-H$;4) each $R_b, R_c, R_d, R_e, R_l, R_j, R_k, R_l$, R_m , is $-H$; R_f is $-CH_3$; R_g is $-OH$; and Z'' is $>CH_2$; then

- 32 -

$$\begin{array}{c} \text{O} \\ | \\ \text{Z}' \end{array}$$

Z' is not $>\text{COCH}_3$ or $>\text{COCCH}_3$; and
 each R_a , R_o independently or together
 are not $-\text{OCH}_3$ or $-\text{H}$;

5

and

- 5) each R_c , R_e , R_j , R_k , R_l , R_m , R_o is $-\text{H}$;
 R_a is $-\text{H}$ or $-\text{OCH}_3$;
 R_b is $-\text{H}$ or $-\text{CH}_3$;
 R_d is $-\text{OH}$;
 R_f is $-\text{CH}_3$;
 R_g is $=\text{O}$;
 R_i is $-\text{OH}$, $=\text{O}$ or $-\text{C}\equiv\text{CH}$; and
 Z'' is $>\text{CH}_2$; then

10


15

$$\begin{array}{c} \text{O} \\ | \\ \text{Z}' \end{array}$$

Z' is not $>\text{COH}$; $>\text{COCCH}_3$, or $-\text{H}$;

where, in each formula set forth above, each R_1 and R_2
 independently is $-\text{H}$, or substituted or unsubstituted
 alkyl, alkenyl or alkynyl group of 1-6 carbons.

8. A compound of the general formula below, said
 compound being a cell-mitosis-inhibiting compound:



- 33 -

wherein:

I. R_a-R_k are defined as follows:

5 A) each $R_a, R_b, R_c, R_d, R_g, R_h, R_i, R_k$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, \text{ or } -I$; and R_e is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;

or

10 B) each R_a, R_b, R_c, R_d, R_k is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, \text{ or } -I$; and each R_g, R_h, R_i independently is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -Br, \text{ or } -I$; and R_e is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -Br, -I$ or $-C\equiv CH$;

15 and

I. Z' is defined as follows:

20 A) Z' is X , where X is $>COR_1, >\overset{O}{\underset{|}{C}}C-R_1, >\overset{O}{\underset{|}{C}}C-OR_1, >\overset{OH}{\underset{|}{C}}C-R_1, >\overset{OH}{\underset{|}{C}}C-OR_1$;

or

25 B) Z' is $=\underset{\underset{R_n}{|}}{C}-X'-$ or $-X'-\underset{\underset{R_n}{|}}{C}=$, where R_n is $-R_1, -OR_1, -SR_1, -F, -NHR_2, -Br$ or $-I$, and X' is X , as defined above; or X' is also $>C=O$;


30 and

II. Z'' is defined as follows:



- 34 -

A) Z" is Y, where Y is $\overset{\text{R}_1}{\underset{|}{\text{O}}}$ -, $\overset{\text{R}_1}{\underset{|}{\text{N}}}$ -, >CHR_1 ,



5





10




15





20



25




30



or

35


B) Z" is -Y-CH- or -CH-Y- , where R_p is



- 35 -

where, in each formula set forth above, each R_1 and R_2 independently is -H, or substituted or unsubstituted alkyl, alkenyl or alkynyl group of 1-6 carbons.

9. A compound of the general formula below, said compound being a cell-mitosis-inhibiting compound:



wherein:

I. R_a - R_o are defined as follows:

- 10 A) each R_a , R_b , R_c , R_d , R_e , R_f , R_i , R_j , R_k , R_l , R_m , R_o independently is - R_1 , - OR_1 , - $OCOR_1$, - SR_1 , -F, - NHR_2 , -Br, or -I; and R_g is - R_1 , - OR_1 , - $OCOR_1$, - SR_1 , -F, - NHR_2 , -Br, -I or - $C\equiv CH$;

or

- 15 B) each R_a , R_b , R_c , R_f , R_k , R_l , independently is - R_1 , - OR_1 , - $OCOR_1$, - SR_1 , -F, - NHR_2 , -Br, or -I; and each R_d , R_e , R_i , R_j , R_m , R_o independently is =O, - R_1 , - OR_1 , - $OCOR_1$,

- 36 -

-SR₁, -F, -NHR₂, -Br, -I; and R_g is =O,
 -R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₂, -Br,
 -I or -C≡CH;

and

5 II. Z is defined as follows:

A) Z is Y, where Y is $\begin{array}{c} \text{R}_1 \\ | \\ -\text{O}-, -\text{N}-, >\text{CHR}_1, \end{array}$

10

$\begin{array}{c} \text{R}_1 \\ | \\ >\text{C}=\text{O}, >\text{C}-(\text{CH}_2)_n\text{OR}_2, \end{array}$

15

$\begin{array}{c} \text{R}_1 \quad \text{O} \quad \text{R}_1 \quad \text{O} \\ | \quad | \quad | \quad | \\ >\text{C}-(\text{CH}_2)_n-\text{CR}_2, >\text{C}-(\text{CH}_2)_n-\text{C}-\text{OR}_2, \end{array}$

20

$\begin{array}{c} \text{R}_1 \quad \text{OH} \\ | \quad | \\ >\text{C}-(\text{CH}_2)_n-\text{CHR}_2, \end{array}$

$\begin{array}{c} \text{R}_1 \quad \text{OH} \\ | \quad | \\ >\text{C}-(\text{CH}_2)_n-\text{CH}-\text{OR}_2, \end{array}$

$\begin{array}{c} \text{R}_1 \quad \text{O} \quad \text{R}_1 \quad \text{OH} \\ | \quad | \quad | \quad | \\ >\text{C}-\text{NH}(\text{CH}_2)_n-\text{CR}_2, >\text{C}-\text{NH}(\text{CH}_2)_n-\text{CHR}_2, \end{array}$

25

$\begin{array}{c} \text{R}_1 \quad \text{OH} \\ | \quad | \\ >\text{C}-\text{NH}(\text{CH}_2)_n-\text{CH}-\text{OR}_2, \end{array}$

30


$\begin{array}{c} \text{R}_1 \quad \text{O} \quad \text{R}_1 \\ | \quad | \quad | \\ >\text{C}-\text{NH}(\text{CH}_2)_n-\text{C}-\text{OR}_2, >\text{C}-\text{NH}(\text{CH}_2)_n-\text{OR}_2, \end{array}$

35


$\begin{array}{c} \text{R}_1 \\ | \\ >\text{C}-\text{NH}(\text{CH}_2)_n-\text{R}_2, \end{array}$

$\begin{array}{c} \text{R}_1 \quad \text{O} \quad \text{R}_1 \quad \text{O} \\ | \quad | \quad | \quad | \\ >\text{C}-(\text{CH}_2)_n-\text{NHC}-\text{OR}_2, >\text{C}(\text{CH}_2)_n\text{NHCR}_2, \end{array}$


- 37 -



5



or




10

is $-R_1$, $-OR_1$, $-SR_1$, $-F$, $-NHR_2$, $-Br$ or $-I$;

where, in each formula set forth above, each R_1 and R_2 independently is $-H$, or substituted or unsubstituted

15 alkyl, alkenyl or alkynyl group of 1-6 carbons.

10. A compound of the general formula below, said compound being a cell-mitosis-inhibiting compound:



wherein:

20 I. R_a-R_k are defined as follows:

A) each R_a , R_b , R_c , R_d , R_g , R_h , R_i , R_k independently is $-R_1$, $-OR_1$, $-OCOR_1$, $-SR_1$,

- 38 -









-F, -NHR₁, -Br, or -I; and R_e is -R₁,
-OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br, -I or
-C≡CH;

or


- 5 B) each R_a, R_b, R_c, R_d, independently is
-R₁, -OR₁, -OCOR₁, -SR₁, -F, -NHR₁, -Br,
or -I; and each R_g, R_h, R_i, R_k
independently is =O, -R₁, -OR₁, -OCOR₁,
10 -SR₁, -F, -NHR₁, -Br or -I; and R_e is
-R₁, -OR₁, -OCOR₁, -SR₁,
-F, -NHR₁, -Br, -I or -C≡CH;

II. Z is defined as follows:


- 15 1) Z is Y, where Y is $\begin{array}{c} R_1 \\ | \\ -O-, -N-, >CHR_1, \end{array}$



- 39 -




5



or


10



is $-R_1$, $-OR_1$, $-SR_1$, $-F$,
 $-NHR_2$, $-Br$ or $-I$;

where, in each formula set forth above, each R_1 and R_2
 independently is $-H$, or substituted or unsubstituted
 15 alkyl, alkenyl or alkynyl group of 1-6 carbons.

11. A compound of the general formula below, said
 compound being a cell-mitosis-inhibiting compound:



- 40 -

wherein:

I. R_a - R_o are defined as follows:

- 5 A) each $R_a, R_b, R_c, R_d, R_e, R_f, R_g, R_h, R_j, R_k, R_l, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br$, or $-I$; and R_1 is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;
- or
- 10 B) each $R_a, R_d, R_f, R_j, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCR_1, -SR_1, -F, -NHR_2, -Br, -I$; and each $R_b, R_c, R_e, R_g, R_h, R_k, R_l$ independently is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br$ or $-I$; and R_1 is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br, -I$ or $-C\equiv CH$;
- 15 or
- 20 C) each $R_a, R_b, R_c, R_d, R_f, R_j, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCR_1, -SR_1, -F, -NHR_2, -Br, -I$; and each R_e, R_g, R_h, R_k, R_l independently is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br$ or $-I$; and R_1 is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br, -I$ or $-C\equiv CH$;

25 and

I. Z is defined as follows:

- 30 1) Z is X, where X is $>COR_1, >\overset{O}{\underset{|}{CC}}-R_1, >\overset{O}{\underset{|}{CC}}-OR_1,$
- $>\overset{OH}{\underset{|}{CC}}-R_1, >\overset{OH}{\underset{|}{CC}}-OR$; or

- 41 -


Z is $\begin{array}{c} \text{=C-X'-} \\ | \\ \text{R}_p \end{array}$ or $\begin{array}{c} \text{-X'-C=} \\ | \\ \text{R}_p \end{array}$, where R_p

5

is $-\text{R}_1$, $-\text{OR}_1$, $-\text{SR}_1$, $-\text{F}$, $-\text{NHR}_2$, $-\text{Br}$ or $-\text{I}$; and X' is X , as defined above; or X' is $>\text{C}=\text{O}$;

where, in each formula set forth above, each R_1 and R_2 independently is $-\text{H}$, or substituted or unsubstituted alkyl, alkenyl or alkynyl group of 1-6 carbons; and the
10 bond indicated by $\text{C}\cdots\text{C}$ is absent or, in combination with the $\text{C}-\text{C}$ bond is the unit $\text{HC}=\text{CH}$.

12. A compound of the general formula below, said compound being a cell-mitosis-inhibiting compound:



15 wherein:


I. R_a-R_o are defined as follows:

- 42 -

- 5
or
- 10
or
- 15
and
- 20
- A) each $R_a, R_b, R_c, R_e, R_g, R_h, R_k, R_l, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, \text{ or } -I$; and R_i is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$ or $-C\equiv CH$;
- B) each $R_a, R_e, R_l, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$; and each R_b, R_c, R_g, R_h is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br$ or $-I$; and R_i is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br, -I$ or $-C\equiv CH$;
- C) each $R_a, R_b, R_c, R_e, R_k, R_m, R_n, R_o$ independently is $-R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_2, -Br, -I$; and each R_g, R_h independently is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br$ or $-I$; and R_i is $=O, -R_1, -OR_1, -OCOR_1, -SR_1, -F, -NHR_1, -Br, -I$ or $-C\equiv CH$;

II. Z is defined as follows:

- 25 A) Z is X, where X is $\begin{array}{c} O \\ | \\ >COR_1, >CC-R_1, >CC-OR_1, \end{array}$



or

- 30 B) Z is $\begin{array}{c} R_p \\ | \\ =C-X'- \end{array}$ or $\begin{array}{c} R_p \\ | \\ -X'-C= \end{array}$, where R_p is $-R_1, -OR_1, -SR_1, -F, -NHR_2, -Br$ or $-I$, and X' is X, as defined above;
- 35 or X' is $=O$;

- 43 -

where, in each formula set forth above, each R_1 and R_2 independently is -H, or substituted or unsubstituted alkyl, alkenyl or alkynyl group of 1-6 carbons; and the bond indicated by $C\bullet\bullet\bullet C$ is absent or, in combination with the C-C bond is the unit $HC=CH$.

13. The method of claim 1, wherein said cell-mitosis-inhibiting compound is 2-methoxyestradiol.

14. The method of claim 1, wherein said cell-mitosis-inhibiting compound is 2-fluoroestradiol.

15. The method of claim 1, wherein said cell-mitosis-inhibiting compound is 2-bromoestradiol.

16. The method of claim 1, wherein said cell-mitosis-inhibiting compound is 2-methoxyestrone.

17. The method of claim 1, wherein said cell-mitosis-inhibiting compound is 17-ethynylestradiol.

18. The method of claims 1 or 2 wherein said compound is further characterized in that

A) Z' is $\begin{array}{c} \text{=C-X'-} \\ | \\ R_n \end{array}$ or $\begin{array}{c} \text{-X'-C=} \\ | \\ R_n \end{array}$; and


Z'' is $\begin{array}{c} \text{-Y-CH-} \\ | \\ R_p \end{array}$ or $\begin{array}{c} \text{-CH-Y-} \\ | \\ R_p \end{array}$; or

B) Z' is X; and Z'' is $\begin{array}{c} \text{-Y-CH-} \\ | \\ R_p \end{array}$ or $\begin{array}{c} \text{-CH-Y-} \\ | \\ R_p \end{array}$; or


C) Z' is $\begin{array}{c} \text{=C-X'-} \\ | \\ R_n \end{array}$ or $\begin{array}{c} \text{-X'-C=} \\ | \\ R_n \end{array}$; and Z'' is Y.

- 44 -





19. The method of claims 3 or 4 wherein said compound is further characterized in that Z is




20. The method of claims 5 or 6 wherein said compound is further characterized in that Z is




21. The compound of claims 7 or 8, wherein said compound is further characterized in that



22. The compound of claims 9 or 10, wherein said compound is further characterized in that Z is



23. The compound of claims 11 or 12, wherein said compound is further characterized in that Z is




24. The method of any one of claims 1-6, wherein at least one of $R_a \rightarrow R_p$ is $-OCH_3$.

- 45 -

25. The compound of any one of claims 7-12,
wherein at least one of R_a - R_p is $-OCH_3$.

1/3



2/3




FIG. 2

3/3





FIG. 3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08767

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/177, 178, 179, 182; 552/558, 614, 617, 625, 627

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS online

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- Y	J. Steroid Biochem., Vol. 32, No. 6, issued 1989, J. Seegers et al., "The Cytotoxic Effects of Estradiol-17beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells" pages 797-809, see entire article.	1, 7, 13 ----- 14, 15, 16, 17, 24
X -- Y	Chemical Abstracts, Vol. 105, issued 1986, W.J. Wheeler et al., "Mitotic inhibition and aneuploidy induction by naturally occurring and synthetic estrogens in Chinese hamster cells in vitro", see abstract no. 54822, Mutat. Res., 171(1), 1986, 31-41.	1, 17 ----- 13, 14, 15, 16, 24

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

20 OCTOBER 1994

Date of mailing of the international search report

10 NOV 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

REBECCA BOOK jd

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08767

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1, 3, 7, 9, 24 (each in part), 13-17

Remark on Protest

☐
☐

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/08767

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 31/56; C07J 41/00, 31/00, 13/00, 9/00, 5/00, 7/00, 3/00, 1/00.

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

514/177, 178, 179, 182; 552/516, 522, 523, 524, 525, 535, 536, 540, 541, 542, 543, 544, 548, 549, 550, 551, 552, 553, 554, 555, 557, 558, 559, 560, 562, 563, 564, 565, 566, 567, 569, 571, 572, 573, 575, 582, 583, 584, 585, 599, 603, 604, 605, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 623, 624, 625, 626, 627, 628, 629, 642, 643, 644, 646, 647, 650, 651, 652.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I, claims 1, 3, 7, 9, and 24, each in part, and claims 13-17; directed to a method of making a medicament compound in which the A ring is aromatic and said compound.

Group II, claims 1, 7, 9, 18, 21, each in part, and 25, directed to a method of making a medicament in which the A ring is aromatic and Z^{*} is Y and Y is O.

Group III, claims 1, 7, 9, 18, 21, each in part, and 25, as in Group II, except that Y is N.

Group IV, claims 1, 3, 7, 18, 21, each in part, and 25, as in Group II, except that the A ring is aromatic and contains 7 carbons and the B ring contains 6 carbon atoms.

Group V, claims 1, 3, 7, 9, 18, 21, each in part, and 25, as in Group IV except that the B ring contains 7 carbon atoms.

Group VI, claims 1 and 18, each in part, in which the A ring contains 6 carbon atoms and the B ring contains 7 carbon atoms.

Group VII, claims 1, 3, 7, 18, 25, each in part, and 25, in which A ring is 7 carbon aromatic and the B ring contains carbons, Z^{*} is Y and Y is O.

Group VIII, claims 1, 3, 7, 18, 21, each in part, and 25, as in Group VII in which Y is N.

Group IX, claims 2, 4, 8, 10, 18, 21, each in part, and 25, directed to a method of making a medicament in which the A and C rings are each aromatic.

Group X, claims 2, 8, 10, 18, 21, each in part, and 25, directed to a method of making a medicament compound as in Group IX in which the Z^{*} is Y and Y is O.

Group XI, claims 2, 8, 10, 18, 21, each in part, and 25, as in Group IX in which Y is N.

Group XII, claims 2, 8, 18, 21, each in part, and 25, as in Group IX in which the A ring contains 7 carbon atoms.

Group XIII, claims 2 and 18, each in part, as in Group VIII, in which the B ring contains 7 carbon atoms.

Group XIV, claims 2, 18, 25, each in part, and 25 as in Group XII, in which the B ring contains 7 atoms.

Group XV, claims 2, 8, 10, 18, each in part, and 25 in which the B ring has 7 carbons and Y is O.

Group XVI, claims 2, 8, 18, each in part, and 25 in which the B ring has 7 carbons and Y is N.

Group XVII, claims 3 in part, 19, and 24, directed to a method of making a medicament in which there is a keto group at C3, the A ring is aromatic and the B ring contains 6 carbon atoms.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/08767

Group XVIII, claims 3 in part and 24, directed to a method of making medicament where the B ring contains 7 carbon atoms.

Group XIX, claims 3 in part and 24, as in Group XVIII, where Z^{*} is Y and Y is O.

Group XX, claims 3 in part and 24, as in Group XVII where Y is N.

Group XXI, claims 4 in part, 19, and 24, directed to making a medicament in which there is a keto group at C-3, the A and C rings are aromatic and the B ring contains 7 carbon atoms.

Group XXII, claims 4 in part, and 24, as in Group XXI, in which Z^{*} is Y and Y is O.

Group XXIII, claims 4 in part, and 24 as in Group XXII, in which Y is N.

Group XXIV, claims 5, 11 in part, and 24, 25, directed to a method of making a medicament which contains one 6-membered aromatic ring.

Group XXV, claims 5, 11 in part, and 20, 23, 24, 25, as in Group XXIV, except that the aromatic ring contains 7 carbon atoms.

Group XXVI, claims 6, 12 in part, and 24, 25 as in Group XXIV, except that the compound contains two 6-membered aromatic rings.

Group XXVII, claims 6, 12 in part, 20, and 24, 25, as in Group XXV except that one aromatic ring contains 7 carbon atoms.

and it considers that the International application does not comply with the requirements of unity of invention (Rules 13.1, 13.2, and 13.3) for the reasons indicated below:

The international application shall relate to one invention or a group of inventions so linked as to form a single general inventive concept. The first invention of the category first mentioned and the first recited invention of the other categories related thereto have been considered the main invention, PCT Administrative Instructions, Annex B(II)(i), 37 CFR 1.475(d).